Goldstein Dov A MD
- SEC CIK
- 0001120478
In the past year, 1 open-market sale filing worth $531.8K and no purchases.
Current role at each company
- GANX Gain Therapeutics, Inc.Directoras of Jul 17, 2026
- BIOA BioAge Labs, Inc.Chief Financial Officeras of Apr 24, 2026
- COYA Coya Therapeutics, Inc.Directoras of Jan 6, 2026
- NBSE NeuBase Therapeutics, Inc.Directoras of Sep 12, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $531.8K
- 1 filing
- Net
- −$531.8K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Goldstein Dov A MD as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
BIOA BioAge Labs, Inc.
Chief Financial Officer1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Goldstein Dov A MDChief Financial Officer | SSale | −27.0K | $19.70 | −$531.8K | −54.6%22.4K after | 4 lots10b5-1 |
COYA Coya Therapeutics, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Goldstein Dov A MDDirector | PPurchaseCommon Stock, par value $0.0001 per share | +10.0K | – | – | New position10.0K after | |
| Jan 4, 2023 (view filing) | Jan 3 | 1 day | Goldstein Dov A MDDirector | PPurchaseCommon Stock, par value $0.0001 per share | +5.00K | – | – | –5.00K after | Derivative |